Parkinson’s Disease is a relentless adversary for the human body, and over 10 million people worldwide fight a daily battle against it. Despite more than 65 years of research, current therapies sill only provide symptomatic relief. Join us as our expert panel discusses why Parkinson’s remains so hard to treat, and how cell and gene therapies could potentially offer a paradigm shift from current treatment options.
In this episode of Headlines of the Future, host Piyal Bhoora is joined by Dr. Krystof Bankiewicz, Scientific Chair, Parkinson’s and MSA at AskBio; Dr. Ahmed Enayetallah, Head of Development at Bluerock Therapeutics; and Dr. Patrick Bussfeld, Head of Medical Affairs, Cell & Gene Therapies and Ophthalmology at Bayer.
